Emcure Introduces Second Novo Weight Management Drug

Emcure Pharmaceuticals is launching Poviztra, a new version of Novo Nordisk’s GLP-1 weight management drug, in India. This move increases Emcure's role in the quickly growing market for obesity treatments.

Emcure will market and sell Poviztra as part of an agreement with Novo Nordisk, making them the first Indian company to offer this medication. Novo Nordisk had announced their partnership with Emcure in November.

Poviztra will start at ?8,790 for a month's supply, which includes four injections of the lowest dose. It comes in a once-weekly pen device and five strengths, giving doctors choices for individual patient needs: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a 2.4 mg maintenance dose.

GLP-1 receptor agonists are popular worldwide for helping with weight management and metabolic health. In India, more people are becoming obese, are aware, and have better access to new treatments, which has boosted the demand for these drugs.

Also Read: Unfolding India's Pharma 2025 Story

Emcure plans to reach more patients with effective weight management options and use its strong distribution network in India with Poviztra. This launch shows Emcure's plan to team up with global innovators and introduce unique treatments in India.

Experts say that more branded options like this will likely create more competition among obesity drugs in India. This could make treatments more affordable and available for those wanting to manage their weight long term.